Cargando…

Insight Into the Prospects for RNAi Therapy of Cancer

RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of ol...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Zhili, Liang, Guohui, Cui, Kunli, Liang, Yayu, Wang, Qun, Lv, Shuangyu, Cheng, Xiaoxia, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007863/
https://www.ncbi.nlm.nih.gov/pubmed/33796026
http://dx.doi.org/10.3389/fphar.2021.644718
_version_ 1783672578332688384
author Tian, Zhili
Liang, Guohui
Cui, Kunli
Liang, Yayu
Wang, Qun
Lv, Shuangyu
Cheng, Xiaoxia
Zhang, Lei
author_facet Tian, Zhili
Liang, Guohui
Cui, Kunli
Liang, Yayu
Wang, Qun
Lv, Shuangyu
Cheng, Xiaoxia
Zhang, Lei
author_sort Tian, Zhili
collection PubMed
description RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of oligonucleotide drug to less accessible parts of the body and the high incidence of toxic side effects are encountered. It is therefore imperative to improve their delivery to target sites and reduce their harmful effects on noncancerous cells to harness their full potential. In this study, the role of RNAi in the treatment of COVID-19, the novel coronavirus disease plaguing many countries, has been discussed. This review aims to ascertain the mechanism and application of RNAi and explore the current challenges of RNAi therapy by identifying some of the cancer delivery systems and providing drug information for their improvement. It is worth mentioning that delivery systems such as lipid-based delivery systems and exosomes have revolutionized RNAi therapy by reducing their immunogenicity and improving their cellular affinity. A deeper understanding of the mechanism and challenges associated with RNAi in cancer therapy can provide new insights into RNAi drug development.
format Online
Article
Text
id pubmed-8007863
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80078632021-03-31 Insight Into the Prospects for RNAi Therapy of Cancer Tian, Zhili Liang, Guohui Cui, Kunli Liang, Yayu Wang, Qun Lv, Shuangyu Cheng, Xiaoxia Zhang, Lei Front Pharmacol Pharmacology RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of oligonucleotide drug to less accessible parts of the body and the high incidence of toxic side effects are encountered. It is therefore imperative to improve their delivery to target sites and reduce their harmful effects on noncancerous cells to harness their full potential. In this study, the role of RNAi in the treatment of COVID-19, the novel coronavirus disease plaguing many countries, has been discussed. This review aims to ascertain the mechanism and application of RNAi and explore the current challenges of RNAi therapy by identifying some of the cancer delivery systems and providing drug information for their improvement. It is worth mentioning that delivery systems such as lipid-based delivery systems and exosomes have revolutionized RNAi therapy by reducing their immunogenicity and improving their cellular affinity. A deeper understanding of the mechanism and challenges associated with RNAi in cancer therapy can provide new insights into RNAi drug development. Frontiers Media S.A. 2021-03-16 /pmc/articles/PMC8007863/ /pubmed/33796026 http://dx.doi.org/10.3389/fphar.2021.644718 Text en Copyright © 2021 Tian, Liang, Cui, Liang, Wang, Lv, Cheng and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Tian, Zhili
Liang, Guohui
Cui, Kunli
Liang, Yayu
Wang, Qun
Lv, Shuangyu
Cheng, Xiaoxia
Zhang, Lei
Insight Into the Prospects for RNAi Therapy of Cancer
title Insight Into the Prospects for RNAi Therapy of Cancer
title_full Insight Into the Prospects for RNAi Therapy of Cancer
title_fullStr Insight Into the Prospects for RNAi Therapy of Cancer
title_full_unstemmed Insight Into the Prospects for RNAi Therapy of Cancer
title_short Insight Into the Prospects for RNAi Therapy of Cancer
title_sort insight into the prospects for rnai therapy of cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007863/
https://www.ncbi.nlm.nih.gov/pubmed/33796026
http://dx.doi.org/10.3389/fphar.2021.644718
work_keys_str_mv AT tianzhili insightintotheprospectsforrnaitherapyofcancer
AT liangguohui insightintotheprospectsforrnaitherapyofcancer
AT cuikunli insightintotheprospectsforrnaitherapyofcancer
AT liangyayu insightintotheprospectsforrnaitherapyofcancer
AT wangqun insightintotheprospectsforrnaitherapyofcancer
AT lvshuangyu insightintotheprospectsforrnaitherapyofcancer
AT chengxiaoxia insightintotheprospectsforrnaitherapyofcancer
AT zhanglei insightintotheprospectsforrnaitherapyofcancer